Nutra Pharma (OTCMKTS:NPHC) versus XOMA Royalty (NASDAQ:XOMA) Head-To-Head Review

XOMA Royalty (NASDAQ:XOMA) and Nutra Pharma (OTCMKTS:NPHC) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, analyst recommendations, profitability, risk and earnings.

Volatility & Risk

XOMA Royalty has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Nutra Pharma has a beta of -0.75, indicating that its stock price is 175% less volatile than the S&P 500.

Profitability

This table compares XOMA Royalty and Nutra Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
XOMA Royalty	32.28%	2.91%	1.03%
Nutra Pharma	N/A	N/A	N/A

Insider and Institutional Ownership

95.9% of XOMA Royalty shares are held by institutional investors. 9.1% of XOMA Royalty shares are held by insiders. Comparatively, 61.5% of Nutra Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares XOMA Royalty and Nutra Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XOMA Royalty	$28.49 million	11.46	-$13.82 million	$0.74	35.64
Nutra Pharma	$600,000.00	0.00	-$1.39 million	N/A	N/A

Nutra Pharma has lower revenue, but higher earnings than XOMA Royalty.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for XOMA Royalty and Nutra Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XOMA Royalty	1	1	3	0	2.40
Nutra Pharma	0	0	0	0	0.00

XOMA Royalty currently has a consensus price target of $60.60, suggesting a potential upside of 129.81%. Given XOMA Royalty’s stronger consensus rating and higher possible upside, analysts plainly believe XOMA Royalty is more favorable than Nutra Pharma.

Summary

XOMA Royalty beats Nutra Pharma on 9 of the 11 factors compared between the two stocks.

About XOMA Royalty

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.